Cystic Fibrosis Therapeutics Market

The Global Cystic Fibrosis Therapeutics Market is valued at USD 10.74 Billion in 2022 and is expected to reach USD 30.71 Billion by 2029 with a CAGR of 16.2% over the forecast period.

Global Cystic Fibrosis Therapeutics Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing  prevalence cystic fibrosis, advances in medical research and technological advancements are major factors anticipated to drive the growth of the Global Cystic Fibrosis Therapeutics Market within the forecast period.

Scope–

Cystic fibrosis (CF) is a genetic disorder that affects the respiratory, digestive, and reproductive systems. Cystic Fibrosis (CF) therapeutics refers to the various treatments and medications used to manage the symptoms and slow the progression of cystic fibrosis It is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in a defective CFTR protein. The CFTR protein is responsible for controlling the flow of salt and water in and out of cells. In people with CF, the defective CFTR protein leads to a buildup of thick, sticky mucus in the lungs, pancreas, and other organs. This mucus clogs the airways, making it difficult to breathe and leading to infections and lung damage.

The Covid-19 pandemic has had a mixed impact on the global cystic fibrosis therapeutics market. On the one hand, it has increased awareness of the importance of lung health and the need for new treatments for respiratory diseases like cystic fibrosis. However, it has also disrupted the supply chain for drugs used to treat cystic fibrosis, leading to shortages and delays in treatment for some patients. Additionally, the pandemic has reduced funding available for research and development of new therapies. Despite these challenges, the global cystic fibrosis therapeutics market is expected to continue to grow in the coming years due to advances in research and development and increasing demand for effective treatments.

Global cystic fibrosis therapeutics market is segmented based on drug class, route of administration, distribution channel and region & country level. Based on drug class, the cystic fibrosis therapeutics market is segmented into s pancreatic enzyme supplements, mucolytics, bronchodilators, CFTR modulators, antibiotics and others. Based on route of administration, the cystic fibrosis therapeutics market is segmented into oral and inhale. Based on distribution channel, the cystic fibrosis therapeutics market is segmented into hospital, retail pharmacies and others.

The regions covered in global cystic fibrosis therapeutics market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global cystic fibrosis therapeutics market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

Key Players-

Some of the key players for global cystic fibrosis therapeutics market are -

• AbbVie Inc.
• Gilead Sciences
• Novartis International AG
• Vertex Pharmaceuticals Incorporated
• Proteostasis Therapeutics
• Mylan N.V.
• Hoffmann-La Roche Ltd.
• Sanofi S.A.
• Galapagos NV
• Chiesi Farmaceutici S.p.A.
• Savara Inc.
• Translate Bio Inc.
• Kamada Ltd.
• Alaxia SAS
• Celtaxsys
• Insmed Incorporated
• others

Segmentation-

By Drug Class:-

• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators
• CFTR Modulators
• Antibiotics
• Others

By Route of Administration:

• Oral Drugs
• Inhaled Drugs

By Distribution Channel:

• Hospitals
• Clinics
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Increasing  Prevalence Cystic Fibrosis, Advances in Medical Research and Technological Advancements are Major Factors Anticipated to Drive the Market Growth

One of the major factors driving the market growth of the global cystic fibrosis market is increasing prevalence of cystic fibrosis. As the prevalence of cystic fibrosis continues to rise, there is a growing need for new and effective treatments. For example; according to the Cystic Fibrosis Foundation, in 2019, there were more than 70,000 patients were living with cystic fibrosis. As the prevalence of cystic fibrosis continues to rise, there is a growing need for new and effective treatments which is boosting the market growth of the global cystic fibrosis market.

In addition, advances in medical research, has been a key factor in the development of new treatments for cystic fibrosis. Over the past few decades, significant progress has been made in understanding the genetic and molecular mechanisms underlying cystic fibrosis, which has led to the development of new therapies. For example; Trikafta (elexacaftor/tezacaftor/ivacaftor), which was approved by the FDA in 2019, is a combination therapy that targets the underlying cause of the disease in patients with certain genetic mutations. Another example; Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved the use of ORKAMBI (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) who are ages 12 to less than 24 months and have certain mutations in the CFTR gene.

However, high cost of treatment can limit the access to cystic fibrosis therapeutics which may hinder the growth of the market. In spite of that, expansion of product portfolios may provide opportunities to the  cystic fibrosis therapeutics market as players are expanding their product portfolios through partnerships, collaborations, and acquisitions. The research and development activities in this field may create more opportunities for the further growth of the market.

North America is Expected to Dominate the Global Cystic Fibrosis Therapeutics Market

North America is expected dominate the global cystic fibrosis therapeutics due to high prevalence of cystic fibrosis, advanced healthcare infrastructure and availability of advanced treatment options in this region. For instance; cystic fibrosis is more common in North America than in other parts of the world, with an estimated 30,000 individuals living with the disease in the United States alone. This high prevalence of the disease drives the demand for cystic fibrosis therapeutics in the region. In addition, North America has advanced healthcare infrastructure, which includes well-equipped hospitals and healthcare centers, specialized healthcare professionals, and modern healthcare technologies. This infrastructure supports the research and development of new and innovative cystic fibrosis therapeutics, leading to better patient outcomes. Moreover, availability of advanced treatment options is also boosting the market growth. North America is home to some of the leading biotech and pharmaceutical companies in the world that specialize in cystic fibrosis therapeutics. For instance; on 21^st October 2021, Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation was approved by the U.S. Food and Drug Administration.

Europe is the second-largest market for cystic fibrosis therapeutics due to the growing awareness among people about the disease, the availability of advanced treatment options, and the presence of major market players in the region. Several leading biotech and pharmaceutical companies, such as Vertex Pharmaceuticals, Chiesi, and Roche, have a strong presence in Europe and have made significant investments in the development of cystic fibrosis therapeutics. For example; Vertex Pharmaceuticals has established a research and development center in the UK focused on cystic fibrosis therapeutics which is helping to grow the market growth.

News-

A Biotech Startup Launched with $38M to Develop a Cystic Fibrosis Gene Therapy

On June 21^st, 2022; Carbon Sciences, a Massachusetts-based startup, launched with $38 million in funding to develop a gene therapy for cystic fibrosis. The Series A financing is led by investment firm Agent Capital, which was joined by the venture arm of Japanese drugmaker Astellas as well as the Cystic Fibrosis Foundation and the Longwood Fund, which in 2020 partnered to fund research into new cystic fibrosis therapies.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 10.74 Billion
Base year considered	2021
Forecast Period CAGR %:	16.2%
Market Size Expected in 2029:	USD 30.71 Billion
Tables, Charts & Figures:	175
Pages	300
Key Players/Companies	AbbVie Inc., Gilead Sciences, Inc., Novartis International AG, Vertex Pharmaceuticals Incorporated, Proteostasis Therapeutics, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd., Sanofi S.A., Galapagos NV, Chiesi Farmaceutici S.p.A., Savara Inc., Translate Bio Inc., Kamada Ltd., Alaxia SAS, Celtaxsys, Inc., Insmed Incorporated and others
Segments Covered	By Drug Class, By Route of Administration, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa